HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. Delta Coordinating Committee and Delta Virology Committee.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. Delta Coordinating Committee and Delta Virology Committee.

AIDS. 1999 Jan 14;13(1):57-65. Unique Identifier : AIDSLINE MED/99223952
Medical Research Council Clinical Trials Unit, University College; London Medical School, UK.

Abstract: OBJECTIVE: To assess changes in HIV RNA and their relationship to disease progression. DESIGN AND SETTING: Delta was a randomized double-blind trial comparing zidovudine (ZDV) monotherapy with ZDV plus didanosine (ddI) or ZDV plus zalcitabine (ddC). Participants had AIDS (with CD4 cell counts above 50 x 10(6)/l), AIDS-related complex, or were asymptomatic with CD4 cell counts below 350 x 10(6)/l. The trial included both ZDV-naive and ZDV-experienced participants. PARTICIPANTS: A total of 1280 participants in the Delta trial whose serum samples had been stored at -70 degrees C and who had a minimum of one sample taken before the start of treatment and at least one later sample. METHODS: HIV-1 RNA quantification was performed using the nucleic acid sequence-based amplification HIV-1 RNA quantitative assay with a cut-off of 800 copies/ml. RESULTS: Reductions in HIV RNA by treatment group were consistent with the clinical results; in ZDV-naive participants the maximum median fall occurred at 4 weeks for all three groups (ZDV, 0.54 log10 copies/ml; ZDV-ddI, 1.38 log10 copies/ml; ZDV-ddC, 1.31 log10 copies/ml). On average the reductions were smaller in ZDV-experienced participants but the difference between the monotherapy and combination arms was very similar in ZDV-naive and experienced participants. Baseline HIV RNA levels, adjusted for CD4 cell counts were highly predictive of time to virological response (HIV RNA < 800 copies/ml); HIV RNA nadirs achieved were predictive of survival. Viral load rebound following response was independent of treatment group and previous ZDV therapy. CONCLUSIONS: Virological changes in response to treatment are of value in assessing prognosis and the activity of new therapies; in particular, there is a strong association between the minimum HIV RNA achieved in the first 16 weeks and subsequent clinical response. CD4 cell counts are independently predictive of response.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL Adult Anti-HIV Agents/*THERAPEUTIC USE CD4 Lymphocyte Count Didanosine/*THERAPEUTIC USE Double-Blind Method Female Human HIV Infections/DRUG THERAPY/IMMUNOLOGY/MORTALITY/*VIROLOGY HIV-1/*GENETICS Male Predictive Value of Tests Reverse Transcriptase Inhibitors/*THERAPEUTIC USE *RNA, Viral Support, Non-U.S. Gov't Time Factors Viral Load Zalcitabine/*THERAPEUTIC USE Zidovudine/*THERAPEUTIC USE
990930
A9991341

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .